Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio
Rhea-AI Summary
Anixa Biosciences (NASDAQ: ANIX) has received a Notice of Allowance from the USPTO for a new patent application covering its chimeric antigen receptor-T cell (CAR-T) technology. The allowed claims encompass core methods and compositions fundamental to Anixa's innovative CAR-T approach, which is specifically designed to address challenges in applying CAR-T therapies to solid tumors.
The patent was granted to The Wistar Institute and exclusively licensed to Anixa Biosciences. The company's CAR-T technology is currently being tested in a clinical trial at Moffitt Cancer Center for treating recurrent ovarian cancer patients.
Positive
- Received USPTO Notice of Allowance for CAR-T technology patent
- Exclusive license agreement with The Wistar Institute
- Technology currently in clinical trials for ovarian cancer
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, ANIX gained 2.71%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
The allowed claims in this patent encompass core methods and compositions that are fundamental to Anixa's innovative CAR-T approach. Anixa's CAR-T platform is specifically designed to address the long-standing challenges of applying CAR-T therapies to solid tumors, positioning the program as a potential breakthrough in immuno-oncology. This patent, along with others, was granted to The Wistar Institute and exclusively licensed to Anixa Biosciences. Anixa's CAR-T technology is currently in a clinical trial at Moffitt Cancer Center, treating recurrent ovarian cancer patients.
Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, stated, "This Notice of Allowance further strengthens our growing intellectual property portfolio and reinforces the potential of our robust CAR-T program. Securing foundational patent protection is a vital step in supporting the program's future success and in driving the development of next-generation immunotherapies with the potential to deliver transformative outcomes for patients."
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. These vaccines were developed at Cleveland Clinic and licensed to Anixa Biosciences. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-receives-notice-of-allowance-from-us-patent-and-trademark-office-for-car-t-technology-further-strengthening-its-robust-intellectual-property-portfolio-302427188.html
SOURCE Anixa Biosciences, Inc.
FAQ
What is the significance of Anixa's (ANIX) new patent allowance for CAR-T technology?
How is Anixa's (ANIX) CAR-T technology being currently tested?
Who owns the patent rights for Anixa's (ANIX) CAR-T technology?
What specific problem does Anixa's (ANIX) CAR-T technology address?
